[📢Brenus awarded French Biotech of the year 2024 🏆🎉]

DOWNLOAD PR Bringing the trophy home 🏆🎉 Awarded by France Biotech last night, we are proud to bring back the cup to Lyon this morning and thank our wonderful team and strong partners for their passion and determination to accelerate innovation in oncology. 👏France Biotech: YOU ROCK ! Congratulations for building and coordinating the French […]

📹 Brenus Pharma final pitch “Trophée Biotech” France Biotech

SEE RECORDING PTICH    Bonjour à toutes et tous, Je suis Paul Bravetti le CEO de Brenus Pharma, et je suis très heureux de vous présenter notre technologie. Malgré les avancés thérapeutiques, les patients ont besoin de nouveaux alliés dans la lutte contre le cancer. Si on prend l’exemple du cancer colorectal, il touche 2M […]

🎬 BEHIND THE SCENE – Corinne TORTORELLI, Sr Lead Medical Affairs

🎬 BEHIND THE SCENE – Corinne TORTORELLI (PharmD, Ph.D) Plongez dans l’aventure, racontée par celles et ceux qui la vivent. SEE VIDEO Dans cette interview, Corinne partage son parcours ; et ce qui l’a motivée à rejoindre Brenus Pharma pour la suite de sa carrière en #oncologie, en tant que Sr Lead Medical Affairs. Toujours […]

Join us at BIO Europe Spring

📢 Last chance to schedule a meeting and connect with our CEO Paul Bravetti, at BIO- Europe Spring convention next week. hashtag#BES24 📢 ➡️ A good opportunity to find out the recent achivements we made and the upcoming clinical development plan. Click here : https://lnkd.in/eudjdypq BIO-Europe Spring, the premier springtime partnering event takes place in […]

[📢5M€ to obtain safety and efficacy clinical data in colorectal cancer 🎉]

DOWNLOAD PR   🎉 Brenus Pharma winner of the call for proposals hashtag#FRANCE2030 : 5M€ to obtain safety and efficacy clinical data in colorectal cancer 🎉 Nous sommes fiers d’annoncer que Brenus Pharma a été désignée lauréate de l’appel à projet “Innovations en biothérapies et bioproduction” du programme France 2030. ➡️Ce financement majeur de près […]

Hybridays 2024

Corinne Tortorelli & Léa Perles had the honor last week of participating as a talented #Biotech in the 2nd edition of the #Hybridays dedicated this year to “the next generations of gene and cell therapies”. High-quality expert reviews, strategic discussions during round tables as well as rich discussions (B2B) with stakeholders in the eco-system reinforced […]

Join us at PSCC Innovation Forum 2024

Today, the Paris Saclay Cancer Cluster kicks off its inaugural “Innovation Forum 2024” at the Faculty of Medicine Paris-Saclay. 🚀 We’re excited to start this day dedicated to scientific discoveries, engaging exchanges, and fostering collaboration within our ecosystem. 🤝 We look forward to meet experts, researchers, industry professionals, start-ups, patients, platform developers… in the fight […]

🔔 Project Update | Allogenix Consortium 🔔

🔔 Project Update | Allogenix Consortium 🔔 Our Oncology and Immunology team spent a productive day with our 🤝 partners from InSphero, during which they discussed the progress of the joint Allogenix consortium. 🚀 Launched in November 2022 with a duration of 3 years, the project, funded by the #EUROSTARS Programme, aims to develop a […]

🎬 BEHIND THE SCENE – Léa Perles : Strategic Operation Lead

🎬 BEHIND THE SCENE – Léa Perles (PharmD, MSc) Plongez dans l’aventure, racontée par celles et ceux qui la vivent. SEE VIDEO Dans cette interview, Léa partage son parcours; et son envie d’innover en industrie #pharmaceutique dans une startup comme Brenus Pharma. En tant que chargée de Business développement et Partenariats stratégiques, elle met en […]

Happy New Year 2024 !

Ready for an exciting and thrilling 2024 ! 🚀🟣🧬 Toute l’équipe de Brenus Pharma vous présente ses meilleurs voeux pour la nouvelle année. 🎇 L’année 2023 a été riche en défis, mais toujours ponctuée de fortes rencontres et d’efforts collectifs afin d’ouvrir la voie pour 2024 où nous souhaitons et espérons accomplir de grands succès : → […]

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with broad & higher quality range of tumor antigens